Revolution Medicines has raised legal and competitive concerns against Erasca following recent developments in pancreatic cancer drug research. The dispute follows the release of late-stage clinical data for Revolution’s candidate daraxonrasib.
According to a securities filing by Erasca, Revolution sent a letter asserting that Erasca’s investigational drug, ERAS-0015, is “substantially equivalent” to certain formulations used in daraxonrasib. Revolution stated that continued development and commercialization of ERAS-0015 in the United States would infringe on its patent protections. The company has demanded that Erasca halt all related activities involving the drug, including manufacturing, use, sale, and importation within the U.S.
Revolution also alleged that Erasca made improper comparisons between the two drug candidates. The letter stated that Erasca “improperly compared preclinical data” of ERAS-0015 and daraxonrasib in public disclosures. In addition, Revolution requested that Erasca stop making what it described as deceptive and untrue comparative statements regarding the two treatments.
Erasca responded to these claims by disputing their validity, stating that “the assertions in [Revolution’s] letters are without merit.” The company also indicated that it plans to challenge the allegations, though it did not provide further details.
Erasca separately released Phase 1 dose-escalation data for ERAS-0015 in patients with pancreatic ductal adenocarcinoma who had undergone at least two prior lines of therapy. The company reported an unconfirmed overall response rate of 62% and stated that this result exceeded a comparator by 24 percentage points. The comparator referenced in the announcement was linked to daraxonrasib data from a 2025 publication in the Journal of Thoracic Oncology.
The referenced comparison has drawn attention due to differences in the study context. A corresponding publication identified through database searches reported a 38% confirmed overall response rate for daraxonrasib, though in non-small cell lung cancer rather than pancreatic cancer. Erasca did not specify the exact article in its disclosure.
Earlier in the month, Revolution reported Phase 3 results for daraxonrasib in pancreatic ductal adenocarcinoma, indicating a median overall survival of 13.2 months compared to 6.7 months for patients receiving chemotherapy. Following this announcement, the company’s stock increased by approximately 40%.
Revolution’s shares rose 8% after Monday’s close to $141.94. Erasca’s stock declined nearly 11% by the end of the same trading session to $19.15 and dropped further by more than 42% before Tuesday’s opening bell, reaching $11.09.
Erasca’s update also included the report of a patient death during the trial. A 66-year-old participant receiving ERAS-0015 experienced severe lung inflammation and later discontinued supportive care. During an analyst call, CEO Jonathan Lim indicated that the outcome may have been different if supportive care had continued.
External analysts commented on the case. H.C. Wainwright described it as likely an isolated incident in a complex patient, while J.P. Morgan analyst Anupam Rama similarly characterized it as a one-off case rather than a clear drug-related concern. Wainwright also noted that the event introduces tension with the otherwise benign safety narrative and raises questions regarding attribution and reporting consistency.
Erasca is at the center of a growing legal and competitive conflict after Revolution Medicines challenged the development of its cancer drug candidate ERAS-0015. The dispute highlights increasing tensions in the race to develop next-generation RAS inhibitors for oncology.
The issue arose after Erasca disclosed that Revolution had sent a formal legal letter alleging patent infringement and misuse of proprietary data, raising concerns about the future development pathway of ERAS-0015.
Patent Infringement Allegations Against Erasca
Revolution Medicines claims that ERAS-0015 is “substantially equivalent” to its own patented RAS inhibitor technologies. According to filings, the allegations include infringement under U.S. patent protections and potential liability tied to trade secret misappropriation.
Revolution has demanded that Erasca:
- Halt development and commercialization activities in the U.S.
- Stop manufacturing, selling, or importing ERAS-0015
- Address alleged violations related to intellectual property
These claims underscore the high stakes involved in oncology innovation, particularly in competitive molecular targets like RAS.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
